Moore Capital Management’s Charles River Laboratories CRL Stock Holding History

Moore Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.46M	Buy	43,234 +32,331	+297%	+$5.99M	0.15%	116
2025 Q4	$2.17M	Sell	10,903 -38,022	-78%	-$6.9M	0.03%	362
2025 Q3	$7.65M	Buy	48,925 +22,116	+82%	+$3.51M	0.11%	178
2025 Q2	$4.07M	Sell	26,809 -15,116	-36%	-$2.02M	0.05%	246
2025 Q1	$6.31M	Buy	41,925 +27,438	+189%	+$4.6M	0.13%	159
2024 Q4	$2.67M	Buy	+14,487	New	+$2.79M	0.03%	298
2015 Q3	–	Sell	-65,000	Closed	-$4.57M	–	309
2015 Q2	$4.57M	Buy	+65,000	New	+$4.81M	0.1%	216

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Moore Capital Management's CRL Position: Q1 2026 in Review

Moore Capital Management increased its Charles River Laboratories (CRL) stake by 297% in Q1 2026, buying an estimated $5.99M and bringing the position to 43,234 shares worth $7.46M. The position accounts for 0.15% of the portfolio, ranked #116.

Moore Capital Management first reported a position in CRL in Q2 2015 and has held it in 7 quarters since. The position peaked at $7.65M in Q3 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Moore Capital Management held 43,234 shares of Charles River Laboratories worth $7.46M as of Q1 2026.
Moore Capital Management bought 32,331 Charles River Laboratories shares in Q1 2026, an estimated $5.99M.
Charles River Laboratories made up 0.15% of Moore Capital Management's portfolio in Q1 2026, its #116 holding.
Moore Capital Management first reported a position in Charles River Laboratories in Q2 2015 and has held it in 7 quarters since.
Moore Capital Management's Charles River Laboratories position peaked at $7.65M in Q3 2025.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.